Clicky

MaxCyte, Inc.(MXCT) News

Date Title
Nov 13 MaxCyte Celebrates 25 Years of Innovation Driving Cell Engineering-Based Therapeutics
Oct 10 MaxCyte Appoints Ali Soleymannezhad as Chief Commercial Officer
Oct 9 MaxCyte Inc (MXCT) Q2 2024 Earnings Call Highlights: Revenue Growth Amid Core Challenges
Jul 17 MaxCyte (MXCT) is on the Move, Here's Why the Trend Could be Sustainable
May 29 MaxCyte to Participate in William Blair 44th Annual Growth Stock Conference
May 23 With 64% ownership of the shares, MaxCyte, Inc. (LON:MXCT) is heavily dominated by institutional owners
May 12 MaxCyte, Inc. (NASDAQ:MXCT) Q1 2024 Earnings Call Transcript
May 8 Q1 2024 MaxCyte Inc Earnings Call
May 8 MaxCyte Inc (MXCT) Q1 2024 Earnings Call Transcript Highlights: Robust Revenue Growth and ...
May 7 MaxCyte, Inc. (MXCT) Reports Q1 Loss, Tops Revenue Estimates
May 7 MaxCyte Reports First Quarter 2024 Financial Results and Updates 2024 Guidance
Apr 17 We Think MaxCyte (LON:MXCT) Can Afford To Drive Business Growth
Apr 10 MaxCyte to Report First Quarter 2024 Financial Results on May 7, 2024
Apr 2 MaxCyte Signs Strategic Platform License with Be Biopharma to Support the Development of Engineered B Cell Medicines (BCMs)
Mar 17 Downgrade: Here's How Analysts See MaxCyte, Inc. (LON:MXCT) Performing In The Near Term
Mar 14 MaxCyte, Inc. (LON:MXCT) Just Reported And Analysts Have Been Cutting Their Estimates
Mar 14 MaxCyte, Inc. (NASDAQ:MXCT) Q4 2023 Earnings Call Transcript
Mar 13 MaxCyte's (LON:MXCT) investors will be pleased with their notable 68% return over the last five years
Mar 13 11 Oversold Healthcare Stocks To Buy Right Now
Mar 12 MaxCyte Inc (MXCT) Reports Mixed Financial Results for Q4 and Full Year 2023